Beta counters

RAD51-IN-2 (compound example 67A) is a RAD51 inhibitor extracted from patent WO2019/051465A1In VitroRAD51-IN-2 exhibts an EC 50 of ≤1 μM in activation-induced cytidine deaminase (AID) positive cells. MCE has not independently confirmed the accuracy

RAD51-IN-2 (compound example 67A) is a RAD51 inhibitor extracted from patent WO2019/051465A1In VitroRAD51-IN-2 exhibts an EC 50 of ≤1 μM in activation-induced cytidine deaminase (AID) positive cells. MCE has not independently confirmed the accuracy

PRT 062607.

PRT 062607.

LMT-28 is an orally active and the first synthetic IL-6 inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6-induced phosphorylation of STAT3 , JAK2 , and gp130In VitroLMT-28 reduces

LMT-28 is an orally active and the first synthetic IL-6 inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6-induced phosphorylation of STAT3 , JAK2 , and gp130In VitroLMT-28 reduces

LMT-28 is an orally active and the first synthetic IL-6 inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6-induced phosphorylation of STAT3 , JAK2 , and gp130In VitroLMT-28 reduces

LMT-28 is an orally active and the first synthetic IL-6 inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6-induced phosphorylation of STAT3 , JAK2 , and gp130In VitroLMT-28 reduces

LMT-28 is an orally active and the first synthetic IL-6 inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6-induced phosphorylation of STAT3 , JAK2 , and gp130In VitroLMT-28 reduces

LMT-28 is an orally active and the first synthetic IL-6 inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6-induced phosphorylation of STAT3 , JAK2 , and gp130In VitroLMT-28 reduces

BMS-908662.

BMS-908662.